EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
-2.62 (-5.82%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.88 - 47.64
52 week 19.91 - 63.60
Open 40.90
Vol / Avg. 11.39M/3.14M
Mkt cap 4.78B
P/E     -
Div/yield     -
EPS -2.04
Shares 120.94M
Beta 0.58
Inst. own 82%
Apr 25, 2018
Q1 2018 Exact Sciences Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 15, 2018
Exact Sciences Corp at Barclays Global Healthcare Conference - 9:30AM EDT - Add to calendar
Mar 12, 2018
Exact Sciences Corp at Cowen Health care Conference - 4:50PM EDT - Add to calendar
Feb 22, 2018
Q4 2017 Exact Sciences Corp Earnings Call - Webcast
Feb 22, 2018
Q4 2017 Exact Sciences Corp Earnings Release
Feb 15, 2018
Exact Sciences Corp at Leerink Partners Global Healthcare Conference
Jan 9, 2018
Exact Sciences Corp at JPMorgan Healthcare Conference, Q&A Session
Jan 9, 2018
Exact Sciences Corp at JPMorgan Healthcare Conference - Webcast
Jan 8, 2018
Preliminary Q4 2017 Exact Sciences Corp Earnings Release
Nov 30, 2017
Exact Sciences Corp at Deutsche Bank MedTools and Diagnostics One-on-One Day
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -167.80% -89.97%
Operating margin -26.30% -44.48%
EBITD margin - -38.63%
Return on average assets -99.22% -49.06%
Return on average equity -112.31% -55.93%
Employees 1,268 -
CDP Score - -


441 Charmany Dr
MADISON, WI 53719-1234
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Officers and directors

Kevin T. Conroy Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Jeffrey Thomas Elliott Chief Financial Officer
Age: 39
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President, Director
Age: 48
Bio & Compensation  - Reuters
Graham Peter Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
D. Scott Coward Senior Vice President, General Counsel, Secretary
Age: 52
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 55
Bio & Compensation  - Reuters
James E. Doyle Independent Director
Age: 71
Bio & Compensation  - Reuters
John A. Fallon M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Daniel J. Levangie Independent Director
Age: 66
Bio & Compensation  - Reuters